IsraelMar 24, 2026, 12:31 AM ETAlpha Tau Medical Ltd. (DRTS) StockSean Daly1.74K FollowersCommentsAlpha Tau Medical pioneers localized alpha particle radiation for solid tumors, with its Alpha DaRT technology showing broad applicability and strong early efficacy.2026 is pivotal for DRTS, with multiple clinical trial readouts expected in cSCC, pancreatic, GBM, and prostate cancers, potentially transforming its market standing.Despite a $42.3M operating loss in 2025 and no revenue, DRTS has about five to six quarters of cash, but dilution risk remains high.I recommend a small buy position in DRTS, as its tumor-agnostic, intratumoral approach and the ongoing M&A activity in the radiopharmaceutical space could make it a compelling takeover target.wildpixel/iStock via Getty Images2026 may finally be the year Alpha Tau Medical (DRTS), an under-the-radar Israeli micro-cap, finally shakes off its obscurity. The firm is quietly developing a significant breakthrough in oncology, pioneering the first way of delivering alpha particleThis article was written bySean Daly1.74K FollowersSean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. He has also written extensively on real estate and economic development, exploring issues as diverse as Chinese urbanization, CMI multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds. Global strategy and private equity background. Equity Approach: long/short, event-driven, with a focus on small cap biotech and the emerging markets.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comments